Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy.
Nadia Saoudi GonzálezPaola Valeria MarcheseIosune BaraibarJavier RosFrancesc SalvàMarta RodríguezClara SalvàCaterina VaghiAdriana AlcarazAriadna GarcíaJosep TaberneroElena ÉlezPublished in: Expert opinion on investigational drugs (2024)
G12C variant have emerged, albeit with modest monotherapy activity compared to other tumor types, emphasizing the influence of histologic origins on the EGFR signaling pathway. Integration of EGFR inhibitors into precision medicine has facilitated tailored therapies addressing resistance mechanisms. Patient selection for EGFR inhibitor rechallenge guided by ctDNA findings is crucial, with ongoing investigations exploring novel combinations to enhance EGFR blockade, highlighting the transformative potential of precision medicine in shaping the future of mCRC treatment toward personalized and targeted approaches.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- small cell lung cancer
- signaling pathway
- combination therapy
- randomized controlled trial
- clinical trial
- cancer therapy
- smoking cessation
- oxidative stress
- drug delivery
- epithelial mesenchymal transition
- climate change
- replacement therapy